SRR8518405
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.430
- ALLOGRAFT_REJECTION+0.410
- COMPLEMENT+0.390
- IL6_JAK_STAT3_SIGNALING+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- KRAS_SIGNALING_UP+0.330
- INFLAMMATORY_RESPONSE+0.320
- INTERFERON_GAMMA_RESPONSE+0.310
- PANCREAS_BETA_CELLS+0.250
- IL2_STAT5_SIGNALING+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.490
- MYC_TARGETS_V1-0.490
- G2M_CHECKPOINT-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.400
- MTORC1_SIGNALING-0.390
- CHOLESTEROL_HOMEOSTASIS-0.360
- DNA_REPAIR-0.360
- GLYCOLYSIS-0.330
- ESTROGEN_RESPONSE_LATE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518195 | — | A | 0.922 |
| 2 | 20040019.LumA | — | A | 0.915 |
| 3 | TCGA-BH-A1EU-01A-11R-A137-07 | — | A | 0.904 |
| 4 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.882 |
| 5 | TCGA-AC-A2FF-01A-11R-A17B-07 | — | A | 0.879 |
| 6 | SRR8518276 | — | A | 0.872 |
| 7 | SRR8613704 | — | A | 0.871 |
| 8 | SRR2772780 | — | — | 0.869 |
| 9 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.867 |
| 10 | SRR8518268 | — | A | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |